"Zederman Pharmaceuticals" announced the completion of nearly 100 million yuan in Series A+ financing.

36Kr has learned that according to Zedman's official Weibo, "Zedman Pharma" announced the completion of a nearly 100 million yuan Series A+ financing round. This round of financing is led by Qingdao Guoxin, and the company's existing shareholders, Bainuo Capital, Hankang Capital, and Beda Fund continue to make additional investments. Kaichen Capital continues to serve as the exclusive financial advisor. The funds raised in this round of financing are mainly used to accelerate the research and development, clinical studies, and commercial promotion of multiple therapeutic drugs for autoimmune inflammatory diseases related to the aryl hydrocarbon receptor (AhR) target.